The complement system in systemic autoimmune disease.

[1]  K. Whaley,et al.  Alternative pathway complement activation in rheumatoid arthritis. , 1980, The Journal of rheumatology.

[2]  Simon C Watkins,et al.  The Globular Heads of C1q Specifically Recognize Surface Blebs of Apoptotic Vascular Endothelial Cells1 , 2001, The Journal of Immunology.

[3]  M. Walport,et al.  Complement. Second of two parts. , 2001, The New England journal of medicine.

[4]  M. Dalakas,et al.  Molecular immunology and genetics of inflammatory muscle diseases. , 1998, Archives of neurology.

[5]  D. Mevorach,et al.  Complement-dependent Clearance of Apoptotic Cells by Human Macrophages , 1998, The Journal of experimental medicine.

[6]  S. Nourshargh,et al.  Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. , 2005, Blood.

[7]  M. Walport,et al.  Complement deficiency and immune complex disease , 2005, Springer Seminars in Immunopathology.

[8]  Min Chen,et al.  Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis. , 2009, Rheumatology.

[9]  J. Schalkwijk,et al.  Different mediator systems in biphasic heterologous phase of anti-GBM nephritis in mice. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  P. Aljama,et al.  Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Jianzhu Chen,et al.  A Critical Role of Natural Immunoglobulin M in Immediate Defense Against Systemic Bacterial Infection , 1998, The Journal of experimental medicine.

[12]  N. Sheerin,et al.  Accumulation of immune complexes in glomerular disease is independent of locally synthesized c3. , 2006, Journal of the American Society of Nephrology : JASN.

[13]  A. Blom,et al.  Complement Inhibitor C4b‐Binding Protein in Primary Sjögren’s Syndrome and its Association With Other Disease Markers , 2009, Scandinavian journal of immunology.

[14]  R J Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Salant,et al.  Nephrology Dialysis Transplantation Acute Nephrotoxic Serum Nephritis in Complement Knockout Mice: Relative Roles of the Classical and Alternate Pathways in Neutrophil Recruitment and Proteinuria , 2022 .

[16]  D. Scott,et al.  Epidemiology of vasculitis in Europe , 2001, Annals of the rheumatic diseases.

[17]  M. Sakata,et al.  Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes , 2002, Rheumatology International.

[18]  Pier Paolo Pandolfi,et al.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.

[19]  E. Lewis,et al.  Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  B. Morgan,et al.  Complement: central to innate immunity and bridging to adaptive responses. , 2005, Immunology letters.

[21]  Xiaowei Liu,et al.  Edinburgh Research Explorer Complement C3 activation is required for antiphospholipid antibody-induced fetal loss , 2022 .

[22]  T. Fujita,et al.  The lectin‐complement pathway – its role in innate immunity and evolution , 2004, Immunological reviews.

[23]  L. Truedsson,et al.  Analysis of HLA DR, HLA DQ, C4A, FcγRIIa, FcγRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcγRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility , 2004, Arthritis research & therapy.

[24]  R. Maini,et al.  Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. , 1990, Annals of the rheumatic diseases.

[25]  I. Gigli,et al.  A newly described control mechanism of complement activation in patients with mixed cryoglobulinemia (cryoglobulins and complement). , 1980, The Journal of investigative dermatology.

[26]  M. Carroll,et al.  Protection against anti‐glomerular basement membrane (GBM)‐mediated nephritis in C3‐ and C4‐deficient mice , 1997, Clinical and experimental immunology.

[27]  M. Daha,et al.  Opsonization with C1q and Mannose-Binding Lectin Targets Apoptotic Cells to Dendritic Cells1 , 2004, The Journal of Immunology.

[28]  N. Brot,et al.  C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response , 2000, The Journal of experimental medicine.

[29]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[30]  M. Frank,et al.  Complement resistance in microbes , 2005, Springer Seminars in Immunopathology.

[31]  S. Ruddy,et al.  Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. , 1985, Arthritis and rheumatism.

[32]  P. Heeringa,et al.  The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. , 2005, The American journal of pathology.

[33]  B. Williams,et al.  Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody. , 1976, Clinical and experimental immunology.

[34]  G. D'Amico,et al.  Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  V. M. Holers,et al.  The spectrum of complement alternative pathway‐mediated diseases , 2008, Immunological reviews.

[36]  G. Hughes,et al.  Complement factor 2 deficiency: a clinical and serological family study. , 1992, Annals of the rheumatic diseases.

[37]  M. Walport,et al.  The role of complement in the development of systemic lupus erythematosus. , 2004, Annual review of immunology.

[38]  G. Miller,et al.  A new complement function: solubilization of antigen-antibody aggregates. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Barnum,et al.  Local production of complement proteins in rheumatoid arthritis synovium. , 2002, Arthritis and rheumatism.

[40]  W. Graninger,et al.  Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[41]  C. Ferri,et al.  Cryoglobulinemic vasculitis , 2006, Current opinion in rheumatology.

[42]  G. Kelsoe,et al.  Complement C4 Inhibits Systemic Autoimmunity through a Mechanism Independent of Complement Receptors Cr1 and Cr2 , 2000, The Journal of experimental medicine.

[43]  M. Oppermann,et al.  Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. , 1995, The Journal of rheumatology.

[44]  R. Dwek,et al.  Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein , 1995, Nature Medicine.

[45]  N. Sheerin,et al.  Protection and injury: the differing roles of complement in the development of glomerular injury , 2001, European journal of immunology.

[46]  M. Carroll,et al.  The role of complement in B cell activation and tolerance. , 2000, Advances in immunology.

[47]  T. Rabelink,et al.  Complement activation by tubular cells is mediated by properdin binding. , 2008, American journal of physiology. Renal physiology.

[48]  J. Yagüe,et al.  Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. , 2005, Rheumatology.

[49]  Wiklund Ra,et al.  First of two parts , 1997 .

[50]  J. Ioannidis,et al.  Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. , 2002, Arthritis and rheumatism.

[51]  P. Simmonds,et al.  Extrahepatic Immunologic Manifestations in Chronic Hepatitis C and Hepatitis C Virus Serotypes , 1995, Annals of Internal Medicine.

[52]  M. Walport.  Complement. First of two parts. , 2001, The New England journal of medicine.

[53]  Min Chen,et al.  Novel territory for neutrophils in the pathogenesis of ANCA-associated vasculitides. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  L. Jacobsson,et al.  Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors , 2005, Annals of the rheumatic diseases.

[55]  P. Heeringa,et al.  Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. , 2007, Kidney international.

[56]  Min Chen,et al.  Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[57]  M. Ramos-Casals,et al.  Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjögren's syndrome. , 2008, Rheumatology.

[58]  M. Daha,et al.  Compliments from complement: A fourth pathway of complement activation? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[59]  J. Ahearn,et al.  C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. , 1997, Journal of immunology.

[60]  M. Béné,et al.  Composition of mesangial deposits in IgA nephropathy: complement factors. , 1987, Nephron.

[61]  Min Chen,et al.  Complement Activation Is Involved in Renal Damage in Human Antineutrophil Cytoplasmic Autoantibody Associated Pauci-Immune Vasculitis , 2009, Journal of Clinical Immunology.

[62]  J. Thurman,et al.  The alternative pathway of complement in disease: opportunities for therapeutic targeting. , 2004, Molecular immunology.

[63]  K. Tomooka,et al.  Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide‐related oxygen radicals produced by activated neutrophils , 1992, Clinical and experimental immunology.

[64]  A. Rosen,et al.  Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes , 1994, The Journal of experimental medicine.

[65]  J. Salmon,et al.  Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. , 2008, Journal of reproductive immunology.

[66]  D. Landau,et al.  Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. , 2007, Rheumatology.

[67]  T. Medsger,et al.  Immune complexes in progressive systemic sclerosis (scleroderma). , 1982, Arthritis and rheumatism.

[68]  J. Lambris,et al.  Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. , 2003, The Journal of clinical investigation.

[69]  T. Koike,et al.  Complement activation in patients with primary antiphospholipid syndrome , 2008, Annals of the rheumatic diseases.

[70]  R. Domsic,et al.  Renal biopsy findings predicting outcome in scleroderma renal crisis. , 2009, Human pathology.

[71]  W. Vogt.  Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. , 1996, Immunobiology.

[72]  P. Taylor,et al.  A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo , 2000, The Journal of experimental medicine.

[73]  T. Fujita,et al.  Activation of the lectin complement pathway in Henoch-Schönlein purpura nephritis. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[74]  J. Clauvel,et al.  Biologic and clinical significance of cryoglobulins. A report of 86 cases. , 1974, The American journal of medicine.

[75]  M. Walport,et al.  Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. , 1992, The Journal of clinical investigation.

[76]  P. Lipsky,et al.  New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers , 2003, Current opinion in rheumatology.

[77]  A. Cats,et al.  The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. , 1985, Arthritis and rheumatism.

[78]  Min Chen,et al.  Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Older Patients , 2008, Medicine.

[79]  S. Sereika,et al.  Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. , 1996, Arthritis and rheumatism.

[80]  M. Rastaldi,et al.  Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. , 2006, Journal of the American Society of Nephrology : JASN.

[81]  Min Chen,et al.  Review article: Pathogenic role of complement activation in anti‐neutrophil cytoplasmic auto‐antibody‐associated vasculitis , 2009, Nephrology.

[82]  L. Trouw,et al.  Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation , 2008 .

[83]  S. Ruddy,et al.  Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[84]  P. Bansal,et al.  Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[85]  B. Morgan,et al.  Measurement of terminal complement complexes in rheumatoid arthritis. , 1988, Clinical and experimental immunology.

[86]  P. Pepe,et al.  The kidney in progressive systemic sclerosis: immunohistochemical and antibody elution studies. , 1976, Laboratory investigation; a journal of technical methods and pathology.

[87]  P. Heeringa,et al.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. , 2007, American Journal of Pathology.

[88]  P. Taylor,et al.  Accelerated Nephrotoxic Nephritis Is Exacerbated in C1q-Deficient Mice1 , 2001, The Journal of Immunology.

[89]  Francesco Saverio Tedesco,et al.  Endothelial cells are a target of both complement and kinin system. , 2008, International immunopharmacology.

[90]  Christopher C. Goodnow,et al.  C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.

[91]  M. Dalakas,et al.  Update on idiopathic inflammatory myopathies , 2006, Autoimmunity.

[92]  L. Jacobsson,et al.  Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. , 2004, Arthritis and rheumatism.

[93]  K. Tryggvason,et al.  Alport's syndrome, Goodpasture's syndrome, and type IV collagen. , 2003, The New England journal of medicine.

[94]  A. Mantovani,et al.  Direct binding of C1q to apoptotic cells and cell blebs induces complement activation , 2002, European journal of immunology.

[95]  A. Weintraub,et al.  Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. , 2006, The Journal of clinical investigation.

[96]  D. Gretch,et al.  Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. , 1995, Journal of the American Society of Nephrology : JASN.

[97]  Robert G. Cooper,et al.  Polymyositis and Dermatomyositis , 2022 .

[98]  J. Brown,et al.  Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. , 1992, Journal of clinical & laboratory immunology.

[99]  S. Ruddy,et al.  ACTIVATION OF THE COMPLEMENT AND PROPERDIN SYSTEMS IN RHEUMATOID ARTHRITIS * , 1975, Annals of the New York Academy of Sciences.

[100]  V. Nussenzweig,et al.  Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus , 1982, The Journal of experimental medicine.

[101]  J. Ahearn,et al.  Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. , 1999, Immunopharmacology.

[102]  Y. Matsuzawa,et al.  Complement C1q regulates LPS‐induced cytokine production in bone marrow‐derived dendritic cells , 2004, European journal of immunology.

[103]  D. Abraham,et al.  Overview of pathogenesis of systemic sclerosis. , 2006, Rheumatology.

[104]  I. Olsson,et al.  Cationic proteins of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity. , 1975, Journal of immunology.

[105]  L. Truedsson,et al.  Complement deficiencies and systemic lupus erythematosus , 2007, Autoimmunity.

[106]  D. Vergani,et al.  Activation of the complement system in systemic sclerosis. Relationship to clinical severity. , 1989, Arthritis and rheumatism.

[107]  D. Kilpatrick.  Mannan-binding lectin: clinical significance and applications. , 2002, Biochimica et biophysica acta.

[108]  E. Ritz,et al.  Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. , 1987, Kidney international.

[109]  M. Mizuno,et al.  A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis. , 2006, Current medicinal chemistry.

[110]  Z. Werb,et al.  Netting neutrophils in autoimmune small-vessel vasculitis , 2009, Nature Medicine.

[111]  C. Kallenberg,et al.  SYSTEMIC LUPUS ERYTHEMATOSUS ( SLE ) : the role of apoptosis , 2001 .

[112]  D. Abramowicz,et al.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.

[113]  M. Robson,et al.  Antibody‐mediated glomerulonephritis in mice: the role of endotoxin, complement and genetic background , 2003, Clinical and experimental immunology.

[114]  E. Brown,et al.  Complement receptors and phagocytosis. , 1991, Current opinion in immunology.

[115]  F. Luft,et al.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[116]  McCoy Rc,et al.  The kidney in progressive systemic sclerosis: immunohistochemical and antibody elution studies. , 1976 .

[117]  P. Heeringa,et al.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. , 2002, The Journal of clinical investigation.

[118]  R. Falk,et al.  Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. , 2006, Journal of the American Society of Nephrology : JASN.

[119]  N. Brot,et al.  C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response: Implications for Systemic Autoimmunity , 2000 .

[120]  R. Rodby,et al.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. , 1993, Journal of the American Society of Nephrology : JASN.